

Anand Rohatgi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7259336/publications.pdf>

Version: 2024-02-01

78
papers

5,784
citations

126708

33
h-index

79541

73
g-index

89
all docs

89
docs citations

89
times ranked

9042
citing authors

#	ARTICLE	IF	CITATIONS
1	Soluble Fms-like tyrosine kinase-1 (sFlt-1) is associated with subclinical and clinical atherosclerotic cardiovascular disease: The Dallas Heart Study. <i>Atherosclerosis</i> , 2022, 346, 46-52.	0.4	3
2	High-Density Lipoprotein is Independently Associated with Muscle Mitochondrial Function in Healthy Humans. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
3	Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2021, 6, 179.	3.0	55
4	Stressing the Endothelium to Assess Localized Inflammatory Potential and the Risk for Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 1946-1948.	1.6	4
5	HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. <i>Circulation</i> , 2021, 143, 2293-2309.	1.6	123
6	Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study). <i>PLoS ONE</i> , 2021, 16, e0257574.	1.1	10
7	Molecular Patterns of Extreme and Persistent Cholesterol Efflux Capacity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2588-2597.	1.1	6
8	HDL and Reverse Cholesterol Transport Biomarkers. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 39.	0.5	19
9	Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e018136.	1.6	17
10	Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2020, 76, 781-793.	1.2	48
11	Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity. <i>Circulation</i> , 2020, 142, 657-669.	1.6	49
12	Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS. <i>Journal of the American Heart Association</i> , 2020, 9, e016203.	1.6	3
13	Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension. <i>Circulation</i> , 2019, 140, 2005-2018.	1.6	39
14	Racial Differences in Cardiovascular Biomarkers in the General Population. <i>Journal of the American Heart Association</i> , 2019, 8, e012729.	1.6	58
15	Impaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular Events. <i>Journal of Clinical Medicine</i> , 2019, 8, 2137.	1.0	10
16	Reverse Cholesterol Transport and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2-4.	1.1	24
17	High-Density Lipoprotein and High-Density Lipoprotein Cholesterol. , 2019, , 61-69.		1
18	Effects of Increasing Exercise Intensity and Dose on Multiple Measures of HDL (High-Density) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 T	1.1	43

#	ARTICLE	IF	CITATIONS
19	Novel and Emerging Biomarkers with Risk Predictive Utility for Atherosclerotic Cardiovascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2018, 12, 1.	0.8	0
20	Lipid Measurements. , 2018, , 88-97.		0
21	Is RCT (Reverse Cholesterol Transport) Ready for an RCT (Randomized Controlled Trial)?. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3270-3273.	1.2	3
22	Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk. <i>Journal of Thoracic Disease</i> , 2018, 10, 109-112.	0.6	23
23	JCL roundtable: High-density lipoprotein function and reverse cholesterol transport. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1086-1094.	0.6	20
24	Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2018, 72, 698-700.	1.2	19
25	Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease. <i>Clinical Proteomics</i> , 2018, 15, 10.	1.1	23
26	Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2315-2325.	1.6	154
27	The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S175-S179.	1.8	17
28	Sex-Based Differences in Cardiometabolic Biomarkers. <i>Circulation</i> , 2017, 135, 544-555.	1.6	124
29	Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population. <i>American Heart Journal</i> , 2017, 191, 55-61.	1.2	10
30	Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> , 2017, 263, 156-162.	0.4	32
31	Modulating cholesterol efflux capacity to improve cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2016, 27, 398-407.	1.2	39
32	Beyond Coronary Calcification, Family History, and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2480-2487.	1.2	66
33	Association Between Peptidoglycan Recognition Protein-1 and Incident Atherosclerotic Cardiovascular Disease Events. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2310-2312.	1.2	15
34	HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target. <i>Current Atherosclerosis Reports</i> , 2016, 18, 2.	2.0	46
35	Abstract 97: Association of the Serum Myeloperoxidase/High-Density Lipoprotein Particle Ratio and Incident Cardiovascular Events in a Multi-Ethnic Population: Observations From the Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	1.1	0
36	Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 43.	2.0	27

#	ARTICLE	IF	CITATIONS
37	Relation of Black Race Between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (from the Dallas Heart Study). American Journal of Cardiology, 2015, 115, 890-894.	0.7	36
38	Cholesterol Efflux Capacity as a Therapeutic Target. Journal of the American College of Cardiology, 2015, 66, 2211-2213.	1.2	17
39	Body Fat Distribution and Incident Cardiovascular Disease in Obese Adults. Journal of the American College of Cardiology, 2015, 65, 2150-2151.	1.2	113
40	The association of abnormal findings on transthoracic echocardiography with 2011 Appropriate Use Criteria and clinical impact. International Journal of Cardiovascular Imaging, 2015, 31, 521-528.	0.7	11
41	High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity. Progress in Cardiovascular Diseases, 2015, 58, 32-40.	1.6	71
42	HDL Cholesterol Efflux Capacity and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1869-1872.	13.9	38
43	Coronary Artery Calcium Improves Risk Classification in Younger Populations. JACC: Cardiovascular Imaging, 2015, 8, 1285-1293.	2.3	61
44	Applying a Big Data Approach to Biomarker Discovery. Circulation, 2015, 132, 2289-2292.	1.6	12
45	Abstract 273: HDL Particle Concentration Inversely Associates with Incident Metabolic Syndrome in the Multiethnic Dallas Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0
46	Cardiovascular Lifetime Risk Predicts Incidence of Coronary Calcification in Individuals With Low Short-Term Risk: The Dallas Heart Study. Journal of the American Heart Association, 2014, 3, e001280.	1.6	17
47	The Role of Advanced Lipid Testing in the Prediction of Cardiovascular Disease. Current Atherosclerosis Reports, 2014, 16, 394.	2.0	21
48	HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events. New England Journal of Medicine, 2014, 371, 2383-2393.	13.9	1,113
49	The Relationship of Body Mass and Fat Distribution With Incident Hypertension. Journal of the American College of Cardiology, 2014, 64, 997-1002.	1.2	209
50	Coronary Artery Calcification and Family History of Myocardial Infarction in the Dallas Heart Study. JACC: Cardiovascular Imaging, 2014, 7, 679-686.	2.3	43
51	Statins: Practical Considerations – A Review. European Cardiology Review, 2014, 9, 71.	0.7	5
52	Appropriate Use and Clinical Impact of Transthoracic Echocardiography. JAMA Internal Medicine, 2013, 173, 1600.	2.6	99
53	Discordant effects of rosiglitazone on novel inflammatory biomarkers. American Heart Journal, 2013, 165, 609-614.	1.2	10
54	Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. American Heart Journal, 2013, 165, 43-49.	1.2	23

#	ARTICLE	IF	CITATIONS
55	Soluble ST2 Is Associated with All-Cause and Cardiovascular Mortality in a Population-Based Cohort: The Dallas Heart Study. <i>Clinical Chemistry</i> , 2013, 59, 536-546.	1.5	58
56	Association of Growth Differentiation Factor-15 with Coronary Atherosclerosis and Mortality in a Young, Multiethnic Population: Observations from the Dallas Heart Study. <i>Clinical Chemistry</i> , 2012, 58, 172-182.	1.5	145
57	Lifetime Risks for Cardiovascular Disease Mortality by Cardiorespiratory Fitness Levels Measured at Ages 45, 55, and 65 Years in Men. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1604-1610.	1.2	138
58	Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: The Dallas Heart Study. <i>Atherosclerosis</i> , 2011, 219, 833-838.	0.4	20
59	Clinical applications of advanced lipoprotein testing in diabetes mellitus. <i>Clinical Lipidology</i> , 2011, 6, 371-387.	0.4	14
60	Cardiorespiratory Fitness and Classification of Risk of Cardiovascular Disease Mortality. <i>Circulation</i> , 2011, 123, 1377-1383.	1.6	210
61	Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: From the Dallas Heart Study. <i>Vascular Medicine</i> , 2011, 16, 339-345.	0.8	12
62	Interactions Between Smoking, Pulmonary Surfactant Protein B, and Atherosclerosis in the General Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2136-2143.	1.1	22
63	Separating the Contenders From the Pretenders. <i>Circulation</i> , 2010, 121, 2381-2383.	1.6	9
64	Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2503.	3.8	936
65	Associations of Four Circulating Chemokines with Multiple Atherosclerosis Phenotypes in a Large Population-Based Sample: Results from the Dallas Heart Study. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 339-347.	0.5	36
66	Cholesterol screening in children: makes sense but what is the impact?. <i>Future Cardiology</i> , 2010, 6, 275-280.	0.5	2
67	Assessing Clinical Utility of Carotid Intima-Media Thickness on the Basis of Reclassification. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1068-1069.	1.2	1
68	Circulating lymphotoxin β_2 receptor and atherosclerosis: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> , 2010, 212, 601-606.	0.4	18
69	Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis. <i>Diabetes Care</i> , 2009, 32, 1218-1220.	4.3	83
70	The Report Card on Growth Differentiation Factor 15. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 209-211.	5.1	4
71	Differential Associations Between Soluble Cellular Adhesion Molecules and Atherosclerosis in the Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1684-1690.	1.1	39
72	The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> , 2009, 203, 569-575.	0.4	41

#	ARTICLE	IF	CITATIONS
73	Effects of the Thiazolidinedione Medications on Micro- and Macrovascular Complications in Patients with Diabetes—Update 2008. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 233-240.	1.3	22
74	The association between plasma caspase-3, atherosclerosis, and vascular function in the Dallas Heart Study. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2008, 13, 1281-1289.	2.2	16
75	Hyperthyroidism-Associated Coronary Vasospasm with Myocardial Infarction and Subsequent Euthyroid Angina. <i>Thyroid</i> , 2008, 18, 273-276.	2.4	21
76	Plasma Cytokines, Metabolic Syndrome, and Atherosclerosis in Humans. <i>Journal of Investigative Medicine</i> , 2007, 55, 26-35.	0.7	35
77	HDL Cholesterol: Physiology, Pathophysiology, and Management. <i>Current Problems in Cardiology</i> , 2007, 32, 268-314.	1.1	65
78	Resistin Is an Inflammatory Marker of Atherosclerosis in Humans. <i>Circulation</i> , 2005, 111, 932-939.	1.6	806